JAK2 and inflammatory bowel disease: Interestingly, the heterodimeric IL-12/IL-23 receptors that signal through JAK2 and TYK2 have been successfully targeted in patients with IBD with biologics directed against IL-12/23 (ustekinumab) or IL-23 alone such as guselkumab, risankizumab, and many currently in development.